Trial Profile
Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dovitinib (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 29 Jul 2015 Status changed from active, no longer recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 16 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 12 Nov 2014 New source identified and integrated Mayo clinic 13-001094.